FindTrial
Sign In

PF-05082566

DRUG3 trials

Sponsors

Pfizer

Conditions

Advanced Solid TumorsAdvanced/Metastatic Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellCarcinoma, Squamous Cell of Head and NeckLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Phase 1

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
CompletedNCT01307267
PfizerCarcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck +4
Start: 2011-06-21End: 2019-02-20Updated: 2020-03-17
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
CompletedNCT02179918
PfizerAdvanced Solid Tumors
Start: 2014-08-31End: 2017-02-28Updated: 2019-02-08
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
TerminatedNCT02444793
PfizerAdvanced/Metastatic Solid Tumors
Start: 2015-05-31End: 2017-10-31Updated: 2019-02-27

Related Papers

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Clinical Cancer Research2020-03-0662 citations
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer2019-12-0157 citations
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Clinical Cancer Research2018-03-16274 citations
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Clinical Cancer Research2017-06-20229 citations
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Journal for ImmunoTherapy of Cancer2016-06-0229 citations
Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors.
Journal of Clinical Oncology2016-05-2017 citations
A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.
Journal of Clinical Oncology2015-05-2022 citations
A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.
Journal of Clinical Oncology2014-05-2066 citations